Boehringer Ingelheim Press Releases

Press Release Subscription: Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.

Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers

PRESS RELEASE

Press Release Overview

Here you can find an overview list of our recent Press Releases.

Read more
PRESS RELEASE 17 Sep 2020 at 14:00

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Read more on
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
PRESS RELEASE 16 Sep 2020 at 16:15

Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020

Read more on
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020
PRESS RELEASE 14 Sep 2020 at 13:30

Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

Read more on
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
PRESS RELEASE 11 Sep 2020 at 13:00

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Read more on
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
PRESS RELEASE 10 Sep 2020 at 14:00

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Read more on
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
PRESS RELEASE 27 Aug 2020 at 15:00

Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors

Read more on
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
PRESS RELEASE 18 Aug 2020 at 08:00

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Read more on
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
PRESS RELEASE 17 Aug 2020 at 09:00

Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship

Read more on
Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship
PRESS RELEASE 12 Aug 2020 at 14:00

Phase III InPedILD^™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Read more on
Phase III InPedILD^™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
PRESS RELEASE 03 Aug 2020 at 08:30

First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer Ingelheim

Read more on
First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer Ingelheim
PRESS RELEASE 27 Jul 2020 at 10:00

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health

Read more on
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health
PRESS RELEASE 15 Jul 2020 at 14:45

European Commission approves third nintedanib indication in pulmonary fibrosis¹

Read more on
European Commission approves third nintedanib indication in pulmonary fibrosis¹
PRESS RELEASE 09 Jul 2020 at 14:30

Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action Fund

Read more on
Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action Fund
PRESS RELEASE 07 Jul 2020 at 14:00

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Read more on
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
PRESS RELEASE 02 Jul 2020 at 15:00

Boehringer Ingelheim Launches External Innovation Hub in China

Read more on
Boehringer Ingelheim Launches External Innovation Hub in China
PRESS RELEASE 25 Jun 2020 at 08:00

Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

Read more on
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
PRESS RELEASE 08 Jun 2020 at 14:00

New consortium EUbOPEN will provide tools to unlock disease biology

Read more on
New consortium EUbOPEN will provide tools to unlock disease biology
PRESS RELEASE 04 Jun 2020 at 08:00

“LastMile” – improving through digital

Read more on
“LastMile” – improving through digital
PRESS RELEASE 29 May 2020 at 13:00

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis¹

Read more on
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis¹